| Project/Area Number |
23800045
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Biomedical engineering/Biological material science
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
TOITA Riki 九州大学, 歯学研究院, 助教 (40611554)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Fiscal Year 2012: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | ナノバイオ / 医療・福祉 / バイオテクノロジー / 薬物デリバリー |
|---|
| Research Abstract |
Traditional drug carriers do not have sufficient selectivity to disease cells. In this research, a naturally occurring protein cage, Hsp16.5, was fabricated to selectively deliver cargos into hepatoma cells through chemical and genetic methods. Resulting fabricated Hsp16.5 cages were selectively taken up by hepatoma cells, but not by normal hepatocyte. When conjugate with doxorubicin (DOX) and hepatoma-targetable Hsp were added to hepatoma and normal hepatocyte, cytotoxicity of this conjugates to hepatoma was comparable with that of free DOX, whereas this conjugates drastically reduced cytotoxicity to normal hepatocyte.
|
